Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Intervencionista
Fase 2
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Patrocinador: Fudan University
Última actualización: 14 de agosto de 2024 Aviso: La información proviene de registros públicos y puede no reflejar cambios en tiempo real en el centro local.
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.